- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 721604, 6 pages
The Role of PTPN22 C1858T Gene Polymorphism in Diabetes Mellitus Type 1: First Evaluation in Greek Children and Adolescents
14th Department of Pediatrics, Faculty of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Ring Road Nea Efkarpia, 56403 Thessaloniki, Greece
21st Department of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3Department of Hematology, Papageorgiou General Hospital, Ring Road Nea Efkarpia, 56403 Thessaloniki, Greece
Received 3 April 2013; Revised 27 May 2013; Accepted 20 June 2013
Academic Editor: Timothy B. Niewold
Copyright © 2013 Styliani Giza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. A. M. Gale, “The rise of childhood type 1 diabetes in the 20th century,” Diabetes, vol. 51, no. 12, pp. 3353–3361, 2002.
- S. S. Rich, P. Concannon, H. Erlich et al., “The type 1 diabetes genetics consortium,” Annals of the New York Academy of Sciences, vol. 1079, pp. 1–8, 2006.
- S. Cohen, H. Dadi, E. Shaoul, N. Sharfe, and C. M. Roifman, “Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp,” Blood, vol. 93, no. 6, pp. 2013–2024, 1999.
- X. Yu, J. P. Sun, Y. He et al., “Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 50, pp. 19767–19772, 2007.
- N. Bottini, L. Musumeci, A. Alonso et al., “A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes,” Nature Genetics, vol. 36, no. 4, pp. 337–338, 2004.
- A. Petrone, C. Suraci, M. Capizzi et al., “The protein tyrosine phosphatase nonreceptor 22 (PTPN22) Is associated with high GAD antibody titer in latent autoimmune diabetes in adults: non insulin requiring autoimmune diabetes (NIRAD) study 3,” Diabetes Care, vol. 31, no. 3, pp. 534–538, 2008.
- P. Saccucci, E. Del Duca, N. Rapini et al., “Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy,” Tissue Antigens, vol. 71, no. 3, pp. 234–237, 2008.
- H. Kahles, E. Ramos-Lopez, B. Lange, O. Zwermann, M. Reincke, and K. Badenhoop, “Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population,” European Journal of Endocrinology, vol. 153, no. 6, pp. 895–899, 2005.
- G. Dultz, N. Matheis, M. Dittmar, B. Röhrig, K. Bender, and G. J. Kahaly, “The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes,” Thyroid, vol. 19, no. 2, pp. 143–148, 2009.
- C. Nielsen, D. Hansen, S. Husby, and S. T. Lillevang, “Sex-specific association of the human PTPN22 1858T-allele with type 1 diabetes,” International Journal of Immunogenetics, vol. 34, no. 6, pp. 469–473, 2007.
- W. Zheng and J. X. She, “Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes,” Diabetes, vol. 54, no. 3, pp. 906–908, 2005.
- A. K. Steck, S. Y. Liu, K. McFann et al., “Association of the PTPN22/LYP gene with type 1 diabetes,” Pediatric Diabetes, vol. 7, no. 5, pp. 274–278, 2006.
- D. Smyth, J. D. Cooper, J. E. Collins et al., “Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus,” Diabetes, vol. 53, no. 11, pp. 3020–3023, 2004.
- D. J. Smyth, J. D. Cooper, J. M. M. Howson et al., “PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes,” Diabetes, vol. 57, no. 6, pp. 1730–1737, 2008.
- J. L. Santiago, A. Martínez, H. de la Calle et al., “Susceptibility to type 1 diabetes conferred by the PTPN22 C1858T polymorphism in the Spanish population,” BMC Medical Genetics, vol. 8, article 54, 2007.
- M. Fedetz, F. Matesanz, A. Caro-Maldonado et al., “The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population,” Tissue Antigens, vol. 67, no. 5, pp. 430–433, 2006.
- K. Douroudis, E. Prans, K. Haller et al., “Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population,” Tissue Antigens, vol. 72, no. 5, pp. 425–430, 2008.
- A. Zhernakova, P. Eerligh, C. Wijmenga, P. Barrera, B. O. Roep, and B. P. C. Koeleman, “Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population,” Genes and Immunity, vol. 6, no. 6, pp. 459–461, 2005.
- R. Hermann, K. Lipponen, M. Kiviniemi et al., “Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes,” Diabetologia, vol. 49, no. 6, pp. 1198–1208, 2006.
- C. Chelala, S. Duchatelet, M. L. Joffret et al., “PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits,” Diabetes, vol. 56, no. 2, pp. 522–526, 2007.
- M. Korolija, I. P. Renar, M. Hadžija et al., “Association of PTPN22 C1858T and CTLA-4 A49G polymorphisms with type 1 diabetes in Croatians,” Diabetes Research and Clinical Practice, vol. 86, no. 3, pp. e54–e57, 2009.
- L. C. Stene, K. S. Rønningen, M. Bjørnvold, D. E. Undlien, and G. Joner, “An inverse association between history of childhood eczema and subsequent risk of type 1 diabetes that is not likely to be explained by HLA-DQ, PTPN22, or CTLA4 polymorphisms,” Pediatric Diabetes, vol. 11, no. 6, pp. 386–393, 2010.
- M. Fichna, M. Zurawek, D. Januszkiewicz-Lewandowska, P. Fichna, and J. Nowak, “PTPN22, PDCD1 and CYP27B1 polymorphisms and susceptibility to type 1 diabetes in Polish patients,” International Journal of Immunogenetics, vol. 37, no. 5, pp. 367–372, 2010.
- D. Zhebrun, Y. Kudryashova, A. Babenko et al., “Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population,” Aging, vol. 3, no. 4, pp. 368–373, 2011.
- L. M. Gomez, J. M. Anaya, C. I. Gonzalez et al., “PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases,” Genes & Immunity, vol. 6, no. 7, pp. 628–631, 2005.
- O. Cinek, O. Hradsky, G. Ahmedov et al., “No independent role of the -1123 G > C and + 2740 A > G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,” Diabetes Research and Clinical Practice, vol. 76, no. 2, pp. 297–303, 2007.
- P. C. Chagastelles, M. Romitti, M. R. Trein, E. Bandinelli, B. Tschiedel, and N. B. Nardi, “Association between the 1858T allele of the protein tyrosine phosphatase nonreceptor type 22 and type 1 diabetes in a Brazilian population,” Tissue Antigens, vol. 76, no. 2, pp. 144–148, 2010.
- V. Baniasadi and S. N. Das, “No evidence for association of PTPN22 R620W functional variant C1858T with type 1 diabetes in Asian Indians,” Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 1061–1062, 2008.
- W. W. Lea and Y. H. Lee, “The association between the PTPN22 C1858T polymorphism and systemic lupus erythematosus: a meta-analysis update,” Lupus, vol. 20, no. 1, pp. 51–57, 2011.
- M. C. Totaro, B. Tolusso, V. Napolioni et al., “PTPN22 1858C>T polymorphism distribution in europe and association with rheumatoid arthritis: case-control study and meta-analysis,” PLoS ONE, vol. 6, no. 9, Article ID e24292, 2011.
- Y. H. Lee, S. C. Bae, and G. G. Song, “The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis,” Inflammation Research, vol. 61, no. 5, pp. 411–415, 2012.
- Y. H. Lee, S. J. Choi, J. D. Ji, and G. G. Song, “The association between the PTPN22 C1858T polymorphism and systemic sclerosis: a meta-analysis,” Molecular Biology Reports, vol. 39, no. 3, pp. 3103–3108, 2012.
- L. Luo, B. Cai, F. Liu, X. Hu, and L. Wang, “Association of Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) C1858T gene polymorphism with susceptibility to autoimmune thyroid diseases: a meta-analysis,” Endocrine Journal, vol. 59, no. 5, pp. 439–445, 2012.
- Y. Li, W. Liao, M. Chang et al., “Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22,” Journal of Investigative Dermatology, vol. 129, no. 3, pp. 629–634, 2009.
- M. Roycroft, M. Fichna, D. McDonald et al., “The tryptophan 620 allele of the lymphoid tyrosine phosphatase (PTPN22) gene predisposes to autoimmune Addison's disease,” Clinical Endocrinology, vol. 70, no. 3, pp. 358–362, 2009.
- A. Latiano, O. Palmieri, M. R. Valvano et al., “Evaluating the role of the genetic variations of PTPN22, NFkB1 and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis,” Inflammatory Bowel Diseases, vol. 13, no. 10, pp. 1212–1219, 2007.
- M. I. Zervou, F. Castro-Giner, P. Sidiropoulos, D. T. Boumpas, A. D. Tosca, and S. Krueger-Krasagakis, “The protein tyrosine phosphatase, non-receptor type 22 R620W polymorphism does not confer susceptibility to psoriasis in the genetic homogeneous population of Crete,” Genetic Testing and Molecular Biomarkers, vol. 14, no. 1, pp. 107–111, 2010.
- E. Eliopoulos, M. I. Zervou, A. Andreou et al., “Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete,” Lupus, vol. 20, no. 5, pp. 501–506, 2011.
- H. Peng, M. Zhou, W. D. Xu, et al., “Association of PTPN22 C1858T polymorphism and type 1 diabetes: a meta-analysis,” Immunological Investigations, vol. 41, no. 5, pp. 484–496, 2012.
- S. Tang, W. Peng, C. Wang, H. Tang, and Q. Zhang, “Association of the PTPN22 gene (+1858C/T, -1123G/C) polymorphisms with type 1 diabetes mellitus: a systematic review and meta-analysis,” Diabetes Research and Clinical Practice, vol. 97, no. 3, pp. 446–452, 2012.
- Y. H. Lee and G. G. Song, “Meta-analysis of the family-based association between the PTPN22 C1858T polymorphism and type 1 diabetes,” Molecular Biology Reports, vol. 40, no. 1, pp. 211–215, 2013.
- J. Zheng, S. Ibrahim, F. Petersen, and X. Yu, “Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue,” Genes & Immunity, vol. 13, no. 8, pp. 641–652, 2012.
- X. F. Wang, Z. X. Chen, Y. C. Shao, et al., “Population-based and family-based studies on the protein tyrosine phosphatase non-receptor 22 gene polymorphism and type 1 diabetes: a meta-analysis,” Gene, vol. 517, no. 2, pp. 191–196, 2013.
- C. Xuan, L. M. Lun, J. X. Zhao, et al., “PTPN22 gene polymorphism (C1858T) is associated with susceptibility to type 1 diabetes: a meta-analysis of 19, 495 cases and 25, 341 controls,” Annals of Human Genetics, vol. 77, no. 3, pp. 191–203, 2013.